Bellevue Group AG Sells 3,795 Shares of Certara, Inc. (NASDAQ:CERT)

Bellevue Group AG cut its stake in Certara, Inc. (NASDAQ:CERT) by 4.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 92,129 shares of the company’s stock after selling 3,795 shares during the period. Bellevue Group AG’s holdings in Certara were worth $981,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of CERT. Vanguard Group Inc. raised its holdings in Certara by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 12,437,089 shares of the company’s stock valued at $132,455,000 after acquiring an additional 38,068 shares during the period. ArrowMark Colorado Holdings LLC increased its stake in shares of Certara by 164.2% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock worth $66,171,000 after purchasing an additional 3,861,674 shares during the period. Teacher Retirement System of Texas increased its stake in shares of Certara by 13.9% during the fourth quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company’s stock worth $48,542,000 after purchasing an additional 557,348 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Certara by 4.7% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,083,940 shares of the company’s stock worth $43,494,000 after purchasing an additional 182,042 shares during the last quarter. Finally, Brown Brothers Harriman & Co. boosted its stake in Certara by 63.8% in the 4th quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company’s stock valued at $40,668,000 after purchasing an additional 1,487,998 shares during the period. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Stock Performance

Shares of NASDAQ:CERT opened at $12.99 on Friday. The company’s 50 day simple moving average is $11.70 and its 200 day simple moving average is $11.65. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $17.81. The stock has a market capitalization of $2.10 billion, a price-to-earnings ratio of -64.95, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on CERT shares. Robert W. Baird increased their price objective on Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a research report on Friday, April 11th. Stephens reiterated an “overweight” rating and issued a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. TD Cowen assumed coverage on shares of Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 target price on the stock. KeyCorp lifted their price target on shares of Certara from $15.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, April 16th. Finally, William Blair reissued a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.17.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.